EDAP Provides Corporate Update on US Focal One® Installation Growth
EDAP TMS SA (Nasdaq: EDAP) announced the placement of three Focal One® machines in prestigious U.S. academic centers during Q1 2022, signaling a strong demand for robotic focal therapy. The placements include New York-Presbyterian/Weill Cornell, Beth Israel Deaconess Lahey Health, and UC Davis Medical Center, the latter marking its fourth installation in the University of California Health System. Additionally, five ExactVu micro-ultrasound systems were sold. The company plans to report full financial results for Q1 2022 in mid-May, highlighting ongoing momentum in prostate cancer treatment technologies.
- Strong sales of three Focal One® machines at leading academic institutions in Q1 2022.
- Sale of five ExactVu micro-ultrasound systems further demonstrates market acceptance.
- Expansion into the University of California Health System with four total placements.
- None.
Company announces Focal One® placements at three renowned academic institutions in March
LYON, France, April 12, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent Focal One® placements at select customer sites in the U.S.
During the first quarter 2022, the company sold three Focal One® machines. Notably, all three occurred at prestigious academic and integrated health network reference centers, including: New York-Presbyterian/Weill Cornell Medical Center, Beth Israel Deaconess Lahey Health, an affiliate of Harvard Medical School, and University of California Davis Medical Center in Sacramento. UC Davis represents the company’s fourth placement within the University of California Health System, following earlier placements at UC San Francisco, UC Irvine and UC San Diego.
In addition, the Company announced the sale of five ExactVu micro-ultrasound systems in the US during the first quarter.
Marc Oczachowski, EDAP's Chairman and Chief Executive Officer, said: “The success that we achieved in the U.S. during the first quarter reflects the tireless work of Ryan and the world class team that he has assembled. I am excited that we have had such a strong start to the year.”
Ryan Rhodes, CEO of EDAP U.S., said, “The results in the first quarter further validate the momentum behind focal therapy amongst leading prostate cancer centers in the U.S. We continue to build our organization to support and significantly expand the number of sites using robotic focal HIFU with Focal One® in 2022.”
EDAP plans to report full first quarter 2022 financial and operating results in mid-May.
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
jfraunces@lifesciadvisors.com
FAQ
What recent developments has EDAP made in prostate cancer treatment?
How many Focal One® machines did EDAP sell in Q1 2022?
Which institutions are the new Focal One® placements located at?
What is the significance of UC Davis for EDAP's Focal One®?
When will EDAP report its Q1 2022 financial results?
